A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
Active, not recruiting · Phase 2, Phase 3 · NCT03706365
Conditions: Prostate Cancer
At a glance
- Research payments reported, 2025
- $66,049
- U.S. investigators named
- 13
- Sites paid
- 11
- Planned or actual enrollment
- 393
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Abemaciclib (drug), Placebo (drug), Abiraterone acetate (drug), Prednisone (drug)
- Dates
- Started 2018-11-26; completion 2026-12
- Results posted
- Yes
This study is being done to see how safe and effective abemaciclib is when given together with abiraterone acetate plus prednisone in participants with metastatic castration resistant prostate cancer. Prednisolone may be used instead of prednisone per local regulation.
From ClinicalTrials.gov, last updated 2026-08-07. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $66,049 in research payments for this study in 2025 (14 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Alexandra Drakaki, M.D Internal Medicine · Santa Monica, CA
- Gregg C. Newman, M.D. Hematology & Oncology · Santa Barbara, CA
- Robert M. Jotte, MD Hematology & Oncology · Lone Tree, CO
- Louis C. Garrot, M.D. Hematology & Oncology · Marietta, GA
- John M. Wallmark, M.D. Hematology & Oncology · Rockville, MD
- Gautam G. Jha, MD Hematology & Oncology · Minneapolis, MN
- Anthony Pham, M.D. Hematology & Oncology · Tigard, OR
- Carl G. Chakmakjian, D.O. Medical Oncology · Waco, TX
- Gurjyot K. Doshi, M.D. Hematology & Oncology · Katy, TX
- Sherronda M. Henderson, M.D. Medical Oncology · Temple, TX
- Lijo John, MD Medical Oncology · Longview, TX
- Stephen L. Richey, M.D., M.P.H Hematology & Oncology · Fort Worth, TX
- Steven Ades, MD Hematology & Oncology · Burlington, VT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Texas Oncology PA $15,793
- Univ. of Vermont - Fletcher Allen Health Care, VT $8,090
- Maryland Oncology Hematology PA $5,968
- Sansum Medical Research Foundation $5,953
- Ronald Reagan UCLA Medical Center, CA $5,410
- Northside Hospital Gwinnett, GA $5,400
- Rocky Mountain Cancer Centers LLP $5,345
- Regents of the University of Minnesota $4,662
- Northwest Cancer Specialists PC $4,250
- US Oncology Research LLC $4,179
- Baylor Research Institute $1,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.